Key Insights

Highlights

Success Rate

79% trial completion

Published Results

34 trials with published results (15%)

Research Maturity

76 completed trials (33% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

8.8%

20 terminated out of 227 trials

Success Rate

79.2%

-7.3% vs benchmark

Late-Stage Pipeline

5%

11 trials in Phase 3/4

Results Transparency

45%

34 of 76 completed with results

Key Signals

34 with results79% success20 terminated

Data Visualizations

Phase Distribution

164Total
Not Applicable (66)
Early P 1 (6)
P 1 (50)
P 2 (31)
P 3 (8)
P 4 (3)

Trial Status

Completed76
Recruiting66
Unknown28
Terminated20
Active Not Recruiting14
Withdrawn10

Trial Success Rate

79.2%

Benchmark: 86.5%

Based on 76 completed trials

Clinical Trials (227)

Showing 20 of 20 trials
NCT05384288RecruitingPrimary

Response to Influenza Vaccination in Pediatric Oncology Patients

NCT06579469Recruiting

Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy

NCT06401356Phase 3RecruitingPrimary

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

NCT07570563Phase 1RecruitingPrimary

Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors.

NCT05715047Not ApplicableCompleted

Intervention for Fatigue in HCT Recipients

NCT06689800Not ApplicableRecruitingPrimary

Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy

NCT06131801RecruitingPrimary

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

NCT07052370Phase 1RecruitingPrimary

TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

NCT04552288Phase 2Completed

Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies

NCT05600933Enrolling By Invitation

Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment

NCT03890614Active Not RecruitingPrimary

Novel 3D Hematological Malignancy Organoid to Study Disease Biology and Chemosensitivity

NCT07609485Recruiting

Identifying Cellular and Molecular Determinants of Efficacy and Resistance in Patients Undergoing CAR-T Therapy

NCT06856226Recruiting

Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

NCT07257419Phase 1Recruiting

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

NCT02949427Completed

The Oronasal Microbiota in Pediatric Oncology Patients

NCT05598879Recruiting

Global Cardio Oncology Registry

NCT06566209Terminated

FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis

NCT05887167Phase 1RecruitingPrimary

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

NCT07413991Not ApplicableRecruitingPrimary

Expressive Writing Program Among Young Adults With Blood Cancer

NCT05529069Phase 2Recruiting

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

Scroll to load more

Research Network

Activity Timeline